Supreme Court Preserves Telehealth Access to Abortion Pill, Blocking Restrictions

The Supreme Court stayed a lower court order, preserving nationwide telehealth access to mifepristone.

The U.S. Supreme Court's May 14, 2026 stay keeps mifepristone, a widely used abortion medication, accessible via telehealth and mail while litigation over its distribution rules proceeds. The move temporarily halts a Fifth Circuit decision that would have reinstated in-person dispensing requirements, eliminating mail-order options for patients nationwide.

• Two justices—Clarence Thomas and Samuel Alito—dissented. Justice Alito wrote, “What is at stake is the perpetration of a scheme to undermine our decision in Dobbs.”
• The dispute traces back to Louisiana's challenge of the FDA's 2023 changes, which lifted the in-person rule and allowed pharmacy and mail distribution, arguing these steps violated federal law and state abortion restrictions (KFF).
• Mifepristone, combined with misoprostol, was used in nearly two-thirds of U.S. abortions in 2023, and one in four clinician-provided abortions in 2025 occurred via telehealth.
• In Kansas alone, over 14,300 of 19,800 reported abortions in 2024 involved mifepristone.

Kelly Baden, Vice President for Public Policy at the Guttmacher Institute, said, “The Supreme Court’s administrative stay provides critical short-term relief for patients and providers across the country.”

The stay will last until the Fifth Circuit rules on the appeal and any subsequent Supreme Court petition is addressed (Jurist).

This case highlights the evolving legal landscape on abortion access post-Dobbs and could have significant implications for the FDA’s regulatory authority and telehealth practices.

Yes, but: The Supreme Court's order did not detail its reasoning, leaving future appellate outcomes uncertain.

What's next: The Fifth Circuit will hear the appeal, and further Supreme Court review may follow, affecting the duration of the stay.